MEI Pharma is a biotechnology business based in the US. MEI Pharma shares (MEIP) are listed on the NASDAQ and all prices are listed in US Dollars. MEI Pharma employs 46 staff and has a trailing 12-month revenue of around $66.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.15 |
|---|---|
| 52-week range | $2.73 - $6.91 |
| 50-day moving average | $3.14 |
| 200-day moving average | $4.09 |
| Wall St. target price | $6.00 |
| PE ratio | 0.7908 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $3.92 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.15 from 2024-09-05
| 1 week (2024-08-30) | 1.61% |
|---|---|
| 1 month (2024-08-07) | -8.70% |
| 3 months (2024-06-07) | 9.76% |
| 6 months (2024-03-07) | -11.02% |
| 1 year (2023-09-07) | -41.77% |
|---|---|
| 2 years (2022-09-07) | 552.04% |
| 3 years (2021-09-07) | 9.38% |
| 5 years (2019-09-06) | 82.08% |
Valuing MEI Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEI Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MEI Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, MEI Pharma shares trade at around 1x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
MEI Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 20.6. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEI Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
MEI Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.7 million.
The EBITDA is a measure of a MEI Pharma's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $66.8 million |
|---|---|
| Operating margin TTM | 30.53% |
| Gross profit TTM | $48.8 million |
| Return on assets TTM | 12.4% |
| Return on equity TTM | 61.27% |
| Profit margin | 39.18% |
| Book value | $7.66 |
| Market Capitalization | $20.7 million |
TTM: trailing 12 months
Dividend payout ratio: 32.23% of net profits
Recently MEI Pharma has paid out, on average, around 32.23% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.38% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), MEI Pharma shareholders could enjoy a 0.38% return on their shares, in the form of dividend payments. In MEI Pharma's case, that would currently equate to about $0 per share.
While MEI Pharma's payout ratio might seem fairly standard, it's worth remembering that MEI Pharma may be investing much of the rest of its net profits in future growth.
MEI Pharma's most recent dividend payout was on 5 December 2023. The latest dividend was paid out to all shareholders who bought their shares by 15 November 2023 (the "ex-dividend date").
MEI Pharma's shares were split on a 1:20 basis on 16 April 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MEI Pharma shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for MEI Pharma shares which in turn could have impacted MEI Pharma's share price.
Over the last 12 months, MEI Pharma's shares have ranged in value from as little as $2.7293 up to $6.9099. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MEI Pharma's is 0.73. This would suggest that MEI Pharma's shares are less volatile than average (for this exchange).
MEI Pharma, Inc. , a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.